Planning for patient preference studies begins

Right now, the PREFER consortium and external experts are meeting in Berlin. For two days, we will discuss and agree on methods and study design for patient preference ‘case’ studies in Lung Cancer, Rheumatoid Arthritis and Neuromuscular Disorders. If you are interested to find out more, follow us on twitter #IMIPreferBerlin18.

The aim of the workshop is to create common understanding and agreement on how to prioritise methodological questions and methods for the preference studies we will conduct. We will also match methodological questions to specific studies and agree on design choices. We have also invited scientific experts and stakeholders to exchange ideas and receive critical input.

The workshop starts with two invited keynote lectures by Anne Stiggelbout and Axel Muelbacher. After the workshop, the PREFER Steering Committee will meet and discuss how to move the project from the first phase, where the focus has been on methodology (Link removed) , to the second phase, where we start conducting patient preference studies (Link removed) .

Interested in PREFER? Follow us on twitter @IMI_PREFER and find out more about the workshop at #IMIPreferBerlin18.

By Josepine Fernow

CONTACT US

X: @IMI_PREFER

LinkedIn

YouTube

  •  
  • Disclaimer: This website and its contents reflects the PREFER project's view and not the view of IMI, the European Union or EFPIA.
  •  

PREFER

The Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115966. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).